WAM
CTMX icon

Weiss Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Weiss Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14,497
Closed -$107K – 339
2019
Q3 		$107K Buy
+14,497
New +$143K 0.01% 325

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Weiss Asset Management's CTMX Position: Q4 2019 in Review

Weiss Asset Management sold out of CytomX Therapeutics (CTMX) in Q4 2019, closing a stake of 14,497 shares — an estimated $107K sold.

Weiss Asset Management first reported a position in CTMX in Q3 2019 and held it in 1 quarter. The position peaked at $107K in Q3 2019. 119 funds tracked by Wall St. Rank hold CTMX as of Q4 2019.

  • Weiss Asset Management reported no remaining CytomX Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Weiss Asset Management sold 14,497 CytomX Therapeutics shares in Q4 2019, an estimated $107K.
  • Weiss Asset Management first reported a position in CytomX Therapeutics in Q3 2019 and held it in 1 quarter.
  • Weiss Asset Management's CytomX Therapeutics position peaked at $107K in Q3 2019.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2019.

Based on Weiss Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.